Inactive Instrument

ESSA Pharma Inc Stock price Toronto S.E.

Equities

EPI

CA29668H1047

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * - Capitalization 508M 375M
Net income 2024 * -48M -35.4M Net income 2025 * -78M -57.53M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-10.6 x
P/E ratio 2025 *
-7.53 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.73%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call
Norway's wealth fund pushes for more women on emerging market company boards RE
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Essa Pharma Insider Bought Shares Worth $133,274, According to a Recent SEC Filing MT
Essa Pharma Insider Bought Shares Worth $419,661, According to a Recent SEC Filing MT
ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat CI
ESSA Pharma Files $200 Million Mixed Shelf MT
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer CI
ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors CI
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
ESSA Pharma Signs Clinical Trial Support Deal With Janssen to Evaluate EPI-7386 Combinations to Treat Prostate Cancer MT
ESSA Pharma Inc. Announces Clinical Trial Support Agreement with Janssen Research & Development, LLC CI
More news

Latest transcript on ESSA Pharma Inc

Managers TitleAgeSince
Chief Executive Officer 73 15-06-23
Director of Finance/CFO 66 13-09-30
Chief Operating Officer - 16-07-31
Members of the board TitleAgeSince
Director/Board Member 74 15-03-04
Director/Board Member 68 19-07-30
Chairman 65 10-09-30
More insiders
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
More about the company
  1. Stock
  2. Equities
  3. Stock ESSA Pharma Inc.
  4. Stock ESSA Pharma Inc - Toronto S.E.